Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 2
2007 2
2008 2
2009 3
2010 8
2011 10
2012 4
2013 12
2014 11
2015 19
2016 15
2017 14
2018 17
2019 17
2020 25
2021 23
2022 12
2023 18
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean jin jon kim[Author] (3 results)?
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study.
Moon JS, Park IR, Kim SS, Kim HS, Kim NH, Kim SG, Ko SH, Lee JH, Lee I, Lee BK, Won KC. Moon JS, et al. Among authors: kim sg. Diabetes Metab J. 2023 Nov;47(6):818-825. doi: 10.4093/dmj.2023.0171. Epub 2023 Nov 24. Diabetes Metab J. 2023. PMID: 38043782 Free PMC article. Clinical Trial.
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial.
Kwak SH, Han KA, Kim KS, Yu JM, Kim E, Won JC, Kang JG, Chung CH, Oh S, Choi SH, Won KC, Kim SG, Cho SA, Cho BY, Park KS. Kwak SH, et al. Among authors: kim sg. Diabetes Obes Metab. 2023 Jul;25(7):1865-1873. doi: 10.1111/dom.15046. Epub 2023 Mar 23. Diabetes Obes Metab. 2023. PMID: 36872067 Clinical Trial.
Anagliptin twice-daily regimen improves glycaemic variability in subjects with type 2 diabetes: A double-blind, randomized controlled trial.
Lee YH, Kim DM, Yu JM, Choi KM, Kim SG, Park KS, Son HS, Chung CH, Ahn KJ, Lee SH, Song KH, Kwon SK, Park HK, Won KC, Jang HC; ACACIA Study Group. Lee YH, et al. Among authors: kim sg. Diabetes Obes Metab. 2023 May;25(5):1174-1185. doi: 10.1111/dom.14959. Epub 2023 Jan 10. Diabetes Obes Metab. 2023. PMID: 36564983 Clinical Trial.
198 results